» Articles » PMID: 1949924

Vancomycin Protein Binding in Patients with Infections Caused by Staphylococcus Aureus

Overview
Journal DICP
Specialty Pharmacology
Date 1991 Jul 1
PMID 1949924
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The protein binding of vancomycin has been reported to range from less than 10 percent to 82 percent. We examined the binding of vancomycin in 34 patients (14 intravenous drug abusers, 10 burn patients, and 10 control patients) with Staphylococcus aureus infections. Blood samples were collected serially over an 8- or 12-hour dosing interval following a one-hour infusion. In vitro studies were also performed using albumin solutions of varying concentrations. Binding characteristics were determined through ultrafiltration with vancomycin concentrations analyzed for fluorescence polarization immunoassay. The unbound fraction of vancomycin ranged from 0.41 to 0.77 with a mean of 0.54 +/- 0.08. Unbound fractions was significantly correlated with serum albumin concentration (r = -0.344, p less than 0.046) and renal clearance (r = 0.394, p less than 0.021) but not with total body clearance or volume of distribution. In vitro data also showed an association between albumin concentration and unbound fraction (r = -0.94, p less than 0.017). Although vancomycin protein binding changes with serum albumin, this finding may have limited clinical significance.

Citing Articles

Analytical Validation of Aptamer-Based Serum Vancomycin Monitoring Relative to Automated Immunoassays.

Liu Y, Mack J, Shojaee M, Shaver A, George A, Clarke W ACS Sens. 2023; 9(1):228-235.

PMID: 38110361 PMC: 10826698. DOI: 10.1021/acssensors.3c01868.


Pilot Pharmacokinetic Study in Healthy Adults Using Intravascular Microdialysis Catheters Modified for Use in Paediatric Patients to Assess Vancomycin Blood Levels.

Al Jalali V, Bauer M, Wolfl-Duchek M, Sarhan M, Wicha S, Poschner S Clin Pharmacokinet. 2022; 62(1):77-87.

PMID: 36471223 PMC: 9898326. DOI: 10.1007/s40262-022-01190-7.


Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.

van Groesen E, Innocenti P, Martin N ACS Infect Dis. 2022; 8(8):1381-1407.

PMID: 35895325 PMC: 9379927. DOI: 10.1021/acsinfecdis.2c00253.


Lyophilized Human Bone Allograft as an Antibiotic Carrier: An In Vitro and In Vivo Study.

Coraca-Huber D, Steixner S, Najman S, Stojanovic S, Finze R, Rimashevskiy D Antibiotics (Basel). 2022; 11(7).

PMID: 35884224 PMC: 9312243. DOI: 10.3390/antibiotics11070969.


Pharmacokinetics and pharmacodynamics of peptide antibiotics.

Bian X, Qu X, Zhang J, Nang S, Bergen P, Zhou Q Adv Drug Deliv Rev. 2022; 183:114171.

PMID: 35189264 PMC: 10019944. DOI: 10.1016/j.addr.2022.114171.